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After 24- and 48-hour treatment with 0.05, 0.5 and 5 mg/mL of fumonisin (FB1), beauvericin
(BEA) and ochratoxin A (OTA) alone or combinations of two or all three mycotoxins in equal
concentrations, Giemsa-stained binucleated PK15 cells were scored for the presence of micro-
nuclei (MN), nuclear buds (NBs) and nucleoplasmic bridges (NPBs). Single mycotoxins induc-
ed MN and NPBs in a dose-dependent manner, showing predominantly clastogenic effect. OTA
showed stronger genotoxic potential than FB1 and BEA, since 0.05 and 0.5 mg/mL OTA in-
creased the frequency of MN and NPBs, respectively. Mycotoxin combinations increased the
frequency of MN and NPBs, mostly in additive manner. A dose-dependent increase in NBs was
observed after 24-hour exposure to single mycotoxins. Prolonged treatment with 5 mg/mL of
each toxin alone as well as combined exposure to all mycotoxin concentrations resulted in a
decrease in NBs, which could be related to the extrusion of micronuclei and/or saturation of
the genotoxic effect. This is the first report on genotoxicity of BEA.
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INTRODUCTION
Fumonisin B1 (FB1), beauvericin (BEA) and ochratoxin
A (OTA) are worldwide-distributed mycotoxins, which
contaminate food and feed, particularly maize.1–3 Con-
sumption of FB1-contaminated feed can lead to leukoen-
cephalomalacia in horses, pulmonary oedema in pigs, as
well as hepatotoxicity, nephrotoxicity, immunosuppression
and carcinogenicity in laboratory animals.4–8 FB1 has also
been associated with human oesophageal carcinoma in
southern Africa and China.9,10 Currently available informa-
tions on FB1 genotoxic properties are limited and con-
troversial. Negative results were obtained by the gene mu-
tation assay with Salmonella typhimurium strains TA98,
TA100 and TA 102, SOS chromotest with E. coli strain
PQ37, DNA repair assay with E. coli K-12 strains, and
micronucleus (MN) test with rat reticulocytes.11–13 Evi-
dence of FB1-genotoxicity were reported in the biolumi-
nescence test with Vibrio fischeri and cytogenetic studies
(chromosome aberrations, sister chromatid exchange or
induction of micronuclei) on primary rat hepatocytes, mice
bone marrow cells, rabbit kidney RK13 cells, human
derived hepatoma HepG2 cells, human lymphocytes and
Allium cepa.11,12,14–17
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BEA is a cyclic hexadepsipeptide, which possesses
antimicrobial, insecticidal, cytotoxic, ionophoric, immuno-
suppressive and apoptotic properties.18–22 BEA increases
ion permeability in biological membranes by forming a
complex with essential cations (Ca2+, Na+, K+) and/or by
forming cation-selective channels in lipid membranes,
which may affect ionic homeostasis.23 Save for the non-
mutagenic activity in the Ames mutagenicity assay,24 BEA
has not yet been investigated for inducing MN formation,
as an endpoint for genotoxicity.
OTA is nephrotoxic, carcinogenic, neurotoxic, tera-
togenic and immunosuppressive in laboratory animals.25
Moreover, it has been associated with endemic nephro-
pathy and urinary bladder tumours in humans.26,27 OTA
has produced contradictory results in tests for sister chro-
matid exchange and unscheduled DNA synthesis and did
not induce chromosome aberrations in CHO cells.28 How-
ever, OTA induced sister chromatid exchange in porcine
urinary bladder epithelial cells as well as chromosome
aberrations in human lymphocytes.29,30 Dose-dependent
induction of MN was seen in ovine seminal vesicle cells,
syrian hamster embryo fibroblasts and HepG2 cells.31–33
Moreover, clear genotoxic activity of OTA e.g. DNA ad-
duct formation, was observed in laboratory rodents.34–36
Recently, Fenech and Crott37 have shown that nucleo-
plasmic bridges (NPBs) and nuclear buds (NBs) are good
biomarkers of genomic instability within the cytokinesis-
block micronucleus assay (CBMN). The authors suggest
that the CBMN assay may be a useful model for the
study of the breakage-fusion-bridge cycle (BFB), which
may be one of the mechanisms of rapid development of
cancer cells.
Previously we demonstrated that FB1, BEA and OTA
induced lipid peroxidation and decreased intracellular glu-
tathione levels in porcine kidney PK15 cells. Combined
treatment with two or all of three mycotoxins resulted
mostly in additive effects especially after a 24-hour expo-
sure, although synergistic as well as antagonistic interac-
tions could not be excluded depending on toxin concen-
trations and time of exposure.38 In this study we wanted
to check genotoxic potential of FB1, BEA and OTA gi-
ven alone by analysing MN, NPBs and NBs formation
in porcine kidney PK15 cells, and to explore whether
combinations of FB1, BEA and OTA produce additive,
synergistic or antagonistic effect.
EXPERIMENTAL
Cell Culture and Treatment
Porcine kidney epithelial cells PK15 (American Type Cul-
ture Collection, Rockville, Md USA) were grown in 75 cm2
flasks in DMEM supplemented with 10 % heat-inactivated
FBS, penicillin (100 IU/mL; 1 U ≈ 67.7 mg/mL), streptomy-
cin (100 mg/mL) and amphotericin B (2.5 mg/mL) at 37 °C
in a 5 % CO2. For analysis of MN, NPBs and NBs forma-
tion, cells were seeded on sterile coverslips in 6-well plates.
Plating density ranged from 105 to 106 cells/mL. Mycoto-
xin stock solutions (1 mg/mL) were prepared by dissolving
FB1 in sterile water, and BEA and OTA in ethanol (100 %).
The final concentrations of mycotoxins were obtained by
dilution with the culture medium. The final volume fraction
of ethanol in the medium was up to 0.3 %, which was shown
not to alter cell viability.
Micronucleus, Nucleoplasmic Bridges and Nuclear
Buds Assay
In order to evaluate the frequency of MN, NBs and NPBs
in binucleated cells, the cytokinesis-block micronucelus as-
say was used. PK15 cells were treated with FB1, BEA and
OTA (0.05, 0.5 and 5 mg/mL) for 24 and 48 h, and with
combinations of the two ((0.05 + 0.05), (0.5 + 0.5), and
(5 + 5) mg/mL, respectively) or three mycotoxins ((0.05 +
0.05 + 0.05), (0.5 + 0.5 + 0.5), and (5 + 5 + 5) mg/mL,
respectively). Ethanol was added to control cells in the final
volume fraction of 0.3 %. Cytochalasin B (3 mg/mL), which
inhibits cytokinesis producing two daughter nuclei in the
cytoplasm, was added for 24 h. Mytomycin C (0.03 mmol
dm–3) as standard clastogen and colchicine (1.2 mmol dm–3)
as aneugen were used as positive control. Cell slides were
prepared according to Varga et al.39 with minor modifica-
tions. After the treatment coverslips with cells were washed
in phosphate buffer solution (pH = 7.4) and treated with 0.9 %
NaCl for 5 min at room temperature. Cells on the coverslips
were fixed with methanol-acetic acid (vol. ratio 5:1) mixed
with an equal volume of 0.9 % NaCl. Afterwards, fixation
with undiluted methanol-acetic acid (5:1) was performed
three times. Air-dried slides were stained with 7 % (vol.
fraction) Giemsa in phosphate buffer (pH = 6.8) for visual
counting. 1000 binucleated cells were scored for the pre-
sence of MNs, NBs and NPBs under an oil immersion
microscope according to Fenech and Crott.37
Statistical Analysis
For each experimental point four cultures were treated in
parallel and 1000 cells were evaluated from each culture
for induction of MN, NBs and NPBs. Results represented
as mean ± SEM were statistically analysed by one-way ana-
lysis of variance (ANOVA) followed by a multiple compa-
rison procedure (Tukey test). The level of P<0.05 was con-
sidered statistically significant. To compare the expected with
measured frequency (F), the expected value was calculated
by adding the mean of frequency after exposure to one my-
cotoxin alone (or mixture of two mycotoxines) to the mean
of frequency obtained after exposure to the second or third
substance.38 Expected frequency (Fexpct) was calculated as
follows:
Fexpct (FB1 + BEA) = FFB1 + FBEA – Fcontrol
Fexpct (FB1 + BEA + OTA) =
F(FB1 + BEA) + FOTA – Fcontrol
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Expected SEM (SEMexpct) was calculated as follows:
SEMexpct (FB1 + BEA) = (SEMFB12 + SEMBEA2)1/2
SEM expct (FB1 + BEA + OTA) =
(SEM(FB1 + BEA)2 + SEMOTA2)1/2
The significance of difference between the expected and
measured values was calculated using an unpaired t-test.
The level of P<0.05 was considered statistically significant.
The results were interpreted as follows: an additive effect
was recorded if the measured values were not significantly
above or below the expected values; a synergistic effect was
recorded if the measured values were significantly above
the expected values; an antagonistic effect was recorded if
the measured values were significantly below the expected
values.
RESULTS AND DISCUSSION
In our experiment we scored MN, NBs and NPBs in bi-
nucleated PK15 following the 24- and 48-hour exposure
to FB1, BEA, OTA and their combinations (Table I, II;
Figure 1). The results are presented as the frequency of
MN, NBs and NPBs per 1000 binucleated cells (‰) ±
SEM. We used mytomycin C and colchicine to distinguish
the clastogenic from aneugenic activity of the tested my-
cotoxins. Mytomycin C and colchicine significantly in-
creased the frequencies of MN (about 20 ‰) and NBs
(about 90 ‰) after 24 and 48 h, as compared to 0.3 %
ethanol (about 6 and 60 %, respectively). Only mytomy-
cin C, as standard clastogen, could induce formation of
NPBs (2.8 ‰ and 6 ‰) in PK15 cells.
The results of the CBMN assay show that FB1, BEA
and OTA induce MN in PK15 cells in a dose-dependent
manner. After 24-hour treatment, the lowest concentra-
tion of OTA (0.05 mg/mL) significantly increased MN
frequency (13 ‰) as compared to control (5.7 ‰), while
the same concentrations of FB1 and BEA did not signifi-
cantly affect the formation of MN (7.7 ‰ and 10.7 ‰,
respectively). Treatment with 0.5 mg/mL BEA and OTA
significantly increased frequency of MN (14 ‰ and 16.3
‰, respectively), while with 5 mg/mL all of three myco-
toxins showed almost equal genotoxic potential (MN was
about 17 ‰ and 18 ‰, respectively; P<0.05). Combined
treatment with two or all of the three mycotoxins increased
MN frequency, mostly in additive manner (Figure 2a,b).
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Figure 1. Normal binucleated (BN) PK15 cell (a); BN PK15 cells with 1 micronuclei (MN), treated with 5 mg/mL FB1 for 24 h (b); BN PK15
cells with 2 MN, treated with combination FB1 + BEA, 0.5 mg/mL of each toxin, for 24 h (c); BN PK15 cells with 1 nuclear bud treated with
0.05 mg/mL BEA for 24 h (d); and BN PK15 cells with 1 nucleoplasmic bridge treated with combination BEA + OTA, 0.5 mg/mL of each
toxin, for 24 h (e).
(a) (b) (c)
(d) (e)
A marked increase in MN frequency was observed with
combinations BEA + OTA (37 ‰) and FB1 + BEA + OTA
(40 ‰), at 5 mg/mL doses for each mycotoxin. Treatment
with FB1 + BEA and FB1 + OTA, each given at 5 mg/mL,
produced a similar genotoxic effect (18.6 and 21.7 ‰,
respectively) as the treatment with the same dose of
single toxins. Generally, frequencies of MN after 48-hour
exposure to single toxins or their combinations were not
significantly changed comparing to the results of 24-hour
treatment. Only the three-toxin treatment resulted with
the decrease of MN frequency comparing to the 24-hour
exposure, which could be a consequence of saturation of
the genotoxic effect, or decreased mitotic index and/or
undergoing cell necrosis.
Our findings clearly demonstrate that FB1, BEA and
OTA are genotoxic to PK15. Induction of MN by FB1
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TABLE I. Induction of MN, NBs and NPBs in Giemsa stained binucleated (BN) PK15 cells after 24-hour treatment with FB1, BEA and OTA
given alone or in combination(a)
Treatment MN ± SEM
(‰)
NBs ± SEM
(‰)
NPBs ± SEM
(‰)
ã(FB1) / mg mL
–1
0.05
0.5
5
(7.7 ± 1.3) (c)
(12.6 ± 1.2) (c)
(17.3 ± 1.2) (b),(c)
(58 ± 2.2) (c)
(85.1 ± 3.5) (b)
(88.3 ± 3.8) (b),(c)
(0.0 ± 0.0) (c)
(0.25 ± 0.25) (c)
(4.0 ± 1.5) (c)
ã(BEA) / mg mL–1
0.05
0.5
5
10.7 ± 1.2
(14.0 ± 1.5) (b),(d)
(18.4 ± 2.0) (b),(d)
(62.0 ± 3.6) (d)
(84.3 ± 2.6) (b)
(87.0 ± 3.6) (b),(d)
1.8 ± 0.8
(2.7 ± 0.8) (d)
(7.6 ± 1.4) (b)
ã(OTA) / mg mL–1
0.05
0.5
5
(13.0 ± 1.6) (b)
(16.3 ± 1.8) (b)
(17.3 ± 1.2) (b),(e)
(60.0 ± 4.0) (e)
(90.4 ± 4.6) (b)
(91.0 ± 3.2) (b),(e)
1.8 ± 0.8
(7.0 ± 1.0) (b)
(7.0 ± 1.0) (b)
ã(FB1+BEA) / mg mL
–1
0.05 + 0.05
0.5 + 0.5
5 + 5
(16.3 ± 0.8) (b),(c)
(16.3 ± 0.8) (b)
(18.6 ± 1.2) (b),(f)
(82.3 ± 2.4) (b),(c),(d)
(85.7 ± 2.4) (b)
(101.8 ± 4.5) (b),(f)
3.4 ± 1.2
(6.0 ± 1.0) (b)
(7.6 ± 2.6) (b)
ã(FB1+OTA) / mg mL
–1
0.05 + 0.05
0.5 + 0.5
5 + 5
(14.3 ± 1.2) (b),(c)
(18.4 ± 1.8) (b)
(21.6 ± 1.2) (b),(g)
(88.4 ± 3.0) (b),(c),(e)
(92.0 ± 2.5) (b)
(102.7 ± 2.8) (b),(g)
2.0 ± 1.0
(8.8 ± 2.4) (b),(c)
(10.8 ± 0.8) (b),(c)
ã(BEA+OTA) / mg mL–1
0.05 + 0.05
0.5 + 0.5
5 + 5
(15.3 ± 1.2) (b)
(19.2 ± 1.4) (b)
(37.0 ± 3.2) (b),(d),(e)
(94.7 ± 3.5) (b),(d),(e)
(97.0 ± 4.0) (b)
(51.0 ± 2.6) (d),(e)
(5.0 ± 1.8) (b)
(9.0 ± 1.8) (b)
(7.8 ± 0.4) (b)
ã(FB1+BEA+OTA) / mg mL
–1
0.05 + 0.05 + 0.05
0.5 + 0.5 + 0.5
5 + 5 + 5
(15.7 ± 1.8) (b),(c)
(21.6 ± 2.0) (b),(c),(d)
(40.0 ± 4.3) (b)–(g)
(92.3 ± 3.2) (b)–(e)
(94.0 ± 3.0) (b)
(49.3 ± 3.5) (c)–(g)
(4.8 ± 0.4) (b),(c)
(7.7 ± 0.4) (b),(c)
(8.3 ± 0.8) (b)
Control (h)
Ethanol
Mitomycin C
Colchicine
5.7 ± 1.2
(18.2 ± 2.2) (b)
(21.0 ± 2.0) (b)
59.6 ± 2.3
(90.8 ± 4.6) (b)
(92.0 ± 6.2) (b)
0.0 ± 0.0
2.8 ± 1.0
0.0 ± 0.0
(a) Means of scoring 1000 BN PK15 cells/sample are given.
(b) P<0.05: as compared to the control value.
(c),(d),(e) P<0.05: each toxin taken alone as compared to a combination of two and three toxins in equal concentrations.
(f),(g) P<0.05: two-toxin combination as compared to the combination of three toxins in equal concentrations.
(h) 0.3 % ethanol, 0.03 mmol dm–3 mitomycin C, 1.2 mmol dm–3 colchicine.
was reported for polychromatic erythrocytes in the bone
marrow of mice at the mass ratio of 25 mg/kg, in rabbit
kidney RK13 cells at the concentration of 0.07 mg/mL,
in human derived hepatoma HepG2 cells at 25 mg/mL,
and in human lymphocytes exposed to 5 mg/mL.12,15–17
The observed dominant clastogenic effect of FB1 is in
agreement with these literature reports. The mechanism
by which FB1 could induce genotoxicity is not fully
understood. In vitro and in vivo studies indicate that FB1
can damage DNA indirectly by increasing the oxidative
stress.40 Our previous study demonstrated that FB1 at the
concentration of 0.5 mg/mL significantly decreased the
glutathione level in PK15 cells which is probably due to
the production of reactive oxygen species.38 To our
knowledge, the induction of MN by BEA has not been
reported before. Since BEA acts as an ionophore and in-
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TABLE II. Induction of MN, NBs and NPBs in Giemsa stained binucleated (BN) PK15 cells after 48-hour treatment with FB1, BEA and OTA
given alone or in combination(a)
Treatment MN ± SEM
(‰)
NBs ± SEM
(‰)
NPBs ± SEM
(‰)
ã(FB1) / mg mL
–1
0.05
0.5
5
(6.2 ± 1.2) (c)
(14.0 ± 1.6) (c)
(19.6 ± 1.4) (b),(c)
63.4 ± 2.0
(86.0 ± 3.2) (b),(c)
52.2 ± 2.4
(0.25 ± 0.25) (c)
(0.25 ± 0.25) (c)
(1.6 ± 1.2) (c)
ã(BEA) / mg mL–1
0.05
0.5
5
(7.6 ± 1.2) (d)
(15.2 ± 1.8) (d)
(18.6 ± 1.8) (b),(d)
64.0 ± 3.2
(79.6 ± 3.8) (d)
53.0 ± 5.5
2.0 ± 1.0
(3.6 ± 0.4) (d)
(8.0 ± 1.2) (b)
ã(OTA) / mg mL–1
0.05
0.5
5
(10.4 ± 1.4) (e)
(15.2 ± 1.4) (e)
(17.8 ± 1.8) (b),(e)
65.2 ± 3.8
(83.6 ± 1.8) (b),(e)
53.2 ± 2.8
2.6 ± 0.6
(5.6 ± 1.4) (e)
(7.0 ± 1.5) (b)
ã(FB1+BEA) / mg mL
–1
0.05 + 0.05
0.5 + 0.5
5 + 5
13.2 ± 1.4
(20.2 ± 2.0) (b)
(21.8 ± 3.4) (b)
70.0 ± 4.6
(83.0 ± 1.8) (b),(f)
(46.2 ± 3.8) (b)
3.6 ± 1.4
(7.2 ± 1.8) (b),(c)
(11.0 ± 2.0) (b),(c)
ã(FB1+OTA) / mg mL
–1
0.05 + 0.05
0.5 + 0.5
5 + 5
(12.6 ± 1.2) (g)
(18.0 ± 2.0) (b),(g)
(24.2 ± 2.8) (b)
70.6 ± 1.8
(60.4 ± 3.8) (c),(e)
55.4 ± 2.8
(5.0 ± 1.0) (b),(c)
(8.0 ± 2.0) (b),(c)
(11.0 ± 2.0) (b),(c)
ã(BEA+OTA) / mg mL–1
0.05 + 0.05
0.5 + 0.5
5 + 5
(16.2 ± 1.8) (b),(d)
(29.0 ± 2.5) (b),(d),(e)
(36.0 ± 3.0) (b),(d),(e)
69.0 ± 5.1
(59.4 ± 5.2) (d),(e)
(43.2 ± 4.0) (b)
(7.0 ± 1.4) (b)
(10.0 ± 2.0) (b)
(9.6 ± 1.8) (b)
ã(FB1+BEA+OTA) / mg mL
–1
0.05 + 0.05 + 0.05
0.5 + 0.5 + 0.5
5 + 5 + 5
(22.0 ± 2.0) (b)–(g)
(29.2 ± 3.4) (b)–(g)
(30.0 ± 2.0) (b)–(e)
61.0 ± 7.5
(64.8 ± 5.2) (c),(e),(f)
(40.6 ± 0.6) (b)
(7.0 ± 1.2) (b),(c)
(12.4 ± 2.4) (b)–(e)
(8.0 ± 1.2) (b),(c)
Control (h)
Ethanol
Mitomycin C
Colchicine
6.2 ± 1.4
(21.2 ± 3.2) (b)
(20.0 ± 2.0) (b)
63.4 ± 3.0
(86.8 ± 6.6) (b)
(88.0 ± 4.6) (b)
0.0 ± 0.0
(6.0 ± 2.0) (b)
0.0 ± 0.0
(a) Means of scoring 1000 BN PK15 cells/sample are given.
(b) P<0.05: as compared to the control value.
(c),(d),(e) P<0.05: each toxin taken alone as compared to a combination of two and three toxins in equal concentrations.
(f),(g) P<0.05: two-toxin combination as compared to the combination of three toxins in equal concentrations.
(h) 0.3 % ethanol, 0.03 mmol dm–3 mitomycin C, 1.2 mmol dm–3 colchicine.
creases the intracellular calcium level by increasing the
formation of cation-selective channels in lipid membrane,23
we can speculate that the induction of mitotic disturban-
ces can be related to changes in intracellular calcium con-
centrations. OTA induction of MN was reported for se-
minal vesicle OSV cells, Syrian hamster embryo SHE fi-
broblasts and HepG2 cells at concentrations near 5 mg/mL,
as well as for primary cultures of rat and human kidney
at the concentration of 0.002 mg/mL and 0.05 mg/mL,
respectively.32–34,41 In kinetochore analysis Dopp et al.33
clearly demonstrated that OTA induces predominantly
clastogenic effect, which is in agreement with our find-
ings. OTA also causes an intracellular calcium rise by
enhancing the permeability of the cellular membrane to
calcium, as well as free radical production, which is clo-
sely related to the DNA damage.33,42 These mechanisms
could be the reason for marked additive genotoxic effects,
which were observed after combined treatment of PK15
cells with BEA + OTA. Our previous study showed that
FB1, BEA and OTA decreased glutathione level in PK15
cells in concentrations so low (0.05 and 0.5 mg/mL) that
they did not affect cell viability and lipid peroxidation.
Combined treatment also resulted mostly in additive ef-
fects,38 which correlates with the genotoxic effects of single
and combined toxins. We can speculate that oxidative stress
might be related to genotoxicity of FB1, BEA and OTA.
144 M. [EGVI] KLARI] et al.
Croat. Chem. Acta 81 (1) 139–146 (2008)
Figure 2. Induction of micronuclei (MN) in binucleated (BN) PK15
cells after 24-hour (a) and 48-hour (b) combined treatment with
fumonisin B1 (FB1), beauvericin (BEA) and ochratoxin A (OTA).
Dark bars represent the measured frequency and white bars the
expected frequency. Asterisk (*) represent significant antagonistic
effect (P<0.05).
Figure 3. Induction of nuclear buds (NBs) in binucleated (BN) PK15
cells after 24-hour (a) and 48-hour (b) combined treatment with
fumonisin B1 (FB1), beauvericin (BEA) and ochratoxin A (OTA).
Dark bars represent the measured frequency and white bars the
expected frequency. Asterisk (*) represent significant antagonistic
effect (P<0.05). Two asterisks (**)represent significant synergistic
effect.
Figure 4. Induction of nucleoplasmic bridges (NPBs) in binucleated
(BN) PK15 cells after 24-hour (a) and 48-hour (b) combined treat-
ment with fumonisin B1 (FB1), beauvericin (BEA) and ochratoxin A
(OTA). Dark bars represent the measured frequency and white bars
the expected frequency. Asterisk (*) represent significant antagonistic
effect (P<0.05).
(a)
(b)
(a)
(b)
(a)
(b)
Nuclear budding is a unique mechanism of MN forma-
tion where amplified DNA is localised to a specific site
at the periphery of the nucleus during the S phase of the
cell cycle.43 The NBs have the same morphology as MN
with the exception that they are linked to the nucleus by
a wide or narrow stalk of nucleoplasmic material, which
depends on the stage of budding process. The duration
of budding and final formation of MN is not known.
However, it has been shown that NBs and MN are form-
ed simultaneously after exposure to genotoxins.37 In this
study, the frequency of NBs significantly increased after
24-hour treatment with 0.5 mg/mL of FB1 (85.1 ‰), BEA
(84.3 ‰) and OTA (90.3 ‰), as compared to the control
(59.6 ‰). Combined treatment with 0.05 mg/mL of each
toxin resulted in synergistic increase of NBs, while after
exposure to toxin combinations, each given at 0.5 or 5
mg/mL, additive or antagonistic effects were recorded
(Figure 3a). Exposure of 48 h to mycotoxins given alone
or to their combinations resulted in decrease of NBs com-
paring to the 24-hour treatment (Figure 3b). Decrease of
NBs frequency is probably connected with the extrusion
and formation of micronuclei after 24 h and/or saturation
of genotoxic effect after prolonged exposure to mycotoxin
combinations.
NPBs between nuclei in BN cells have been pro-
posed for scoring in the CBMN assay because they were
observed after exposure to clastogens and are thought to
originate from rearranged chromosomes with more than
one centromere.44 Our results show that OTA (0.5 mg/mL)
and BEA (5 mg/mL) significantly increased the frequen-
cy of NPB (about 7 ‰) after the 24-hour treatment in
respect to the control (0 ‰), while FB1 did not affect
significantly the formation of NPB (0-4 ‰) at any of
concentrations considered. Combined mycotoxin treatment
showed mostly additive genotoxic effect (Figure 4). The
results of scoring NPBs following the 48-hour exposure
to mycotoxins did not differ significantly from the results
obtained for the 24-hour treatment. All three mycotoxins
were predominantly clastogenic as compared to the posi-
tive controls as well as considering the formation of NPBs.
To our knowledge, this study is the first to report induc-
tion of NBs and NPBs by FB1, BEA and OTA.
CONCLUSIONS
FB1, BEA and OTA are genotoxic to PK15, showing
predominant clastogenic effects. All of three mycotoxins
induce MN and NPBs in PK15 cells in a dose-dependent
manner. Combined mycotoxin treatment showed mostly
additive effects in the formation of MN and NPBs. A dose-
dependent increase in NB frequency was observed fol-
lowing the 24-hour mycotoxin treatment. Prolonged expo-
sure to each toxin alone (at the concentration 5 ìg/mL)
as well as combined treatment with all mycotoxin con-
centrations resulted in a decrease in NBs, which could
be related to the extrusion of micronuclei and/or satura-
tion of the genotoxic effect. In conclusion, this study pro-
vides additional evidence for the hypothesis that OTA
and FB1 are carcinogens with genotoxic properties.
Since these mycotoxins were effective in relatively low
concentrations, these effects might also occur in animals
and humans following the consumption of mycotoxin-
contaminated feed and food. This study is the first to re-
port clastogenic effects of BEA in cell cultures.
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SA@ETAK
Genotoksi~nost fumonizina B1, bovericina i okratoksina A u stanicama
bubre`nog epitela svinje (PK15): djelovanje pojedina~nih i kombiniranih mikotoksina
Maja [egvi} Klari}, Stjepan Pepeljnjak i Ru`ica Rozgaj
Stanice bubre`nog epitela svinje (PK15) tretirane su s 0,05, 0,5 i 5 mg/mL fumonizina (FB1), bovericina
(BEA) i okratoksina A (OTA) te kombinacijama dva ili tri mikotoksina u istim koncentracijama tijekom 24 i 48 h.
Binuklearne PK15 stanice (Giemsa bojenje) pretra`ene su na prisutnost mikronukleusa (MN), nuklearnih pu-
pova (NP) i nukleoplazmatskih mostova (NPM). Pojedina~ni toksini inducirali su tvorbu MN i NPM ovisno o
dozi, pokazuju}i dominantno klastogeno djelovanje. OTA ima ja~i genotoksi~ni potencijal od FB1 i BEA, s
obzirom na to da 0,05 i 0,5 mg/mL OTA zna~ajno pove}ava u~estalost MN i NPM. Mikotoksini aplicirani u
kombinaciji uglavnom pokazuju aditivno djelovanje. U~estalost NP pove}ava se ovisno o dozi nakon 24-satnog
tretmana s pojedina~nim toksinima. Dulje izlaganje pojedina~nim mikotoksinima (5 mg/mL) te kombinacijama
toksina u svim koncentracijama dovodi do smanjenja u~estalosti NP, {to se mo`e pripisati odvajanju MN i/ili
zasi}enosti genotoksi~nog djelovanja. Ovo je prvo izvje{}e o genotoksi~nom djelovanju BEA.
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